Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 175
interventional 134
Observational 32
Registry 9

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 80
Drug|placebo 22
Biological 17
Biological|placebo 5
Biological|Drug 2
Drug|Procedure 2
Other 2
Biological|Other 1
Device 1
Drug|Other|placebo 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 27
NA 16
China 15
France 5
Japan 5
Italy 3
Mexico 3
Australia 2
Austria 2
Canada 2
Denmark 2
Egypt 2
Hong Kong 2
Korea, Republic of 2
United Kingdom 2
Belgium 1
Brazil 1
Bulgaria|Romania|Serbia 1
Canada|Netherlands 1
Czechia|Germany|Hungary|Poland 1
Finland 1
Germany|Greece|Hong Kong|Korea, Republic of|New Zealand|Pakistan|Poland|Romania|Russian Federation|Slovenia|Taiwan|Thailand|United Kingdom 1
Germany|Italy|Poland|Russian Federation|Ukraine|United Kingdom 1
Germany|Russian Federation 1
Iran, Islamic Republic of 1
Netherlands 1
Norway 1
Poland 1
Russian Federation 1
Russian Federation|Spain|United Kingdom 1
Taiwan 1
Thailand 1
United States|Argentina|Czech Republic|Germany|Hong Kong|Israel|Italy|Poland|Russian Federation|Spain|Taiwan|Thailand|United Kingdom 1
United States|Argentina|India 1
United States|Australia|Austria|Belgium|Bulgaria|France|Germany|Israel|Italy|Romania|Spain|Switzerland|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Netherlands|Spain|Switzerland|Turkey|United Kingdom 1
United States|Australia|Austria|Bulgaria|Canada|Czechia|Denmark|Hungary|Italy|Netherlands|Norway|Poland|Romania|Spain|United Kingdom 1
United States|Australia|Austria|Canada|China|Czech Republic|Denmark|Finland|France|Germany|Greece|Hong Kong|Italy|Korea, Republic of|Netherlands|New Zealand|Pakistan|Peru|Poland|Romania|Russian Federation|Slovakia|Slovenia|Spain|Sweden|Taiwan|Thailand|Tunisia|Ukraine|United Kingdom|Vietnam 1
United States|Australia|Bulgaria|Canada|Czechia|Netherlands|Norway|United Kingdom 1
United States|Australia|Canada 1
United States|Australia|Canada|Denmark|Hungary|Italy|Netherlands|United Kingdom 1
United States|Australia|Canada|Georgia|Moldova, Republic of|Poland|Russian Federation|United Kingdom 1
United States|Australia|Canada|Spain 1
United States|Australia|Czechia|France|Germany|Italy|Poland|Spain|United Kingdom 1
United States|Australia|New Zealand 1
United States|Austria|Belgium|Canada|Czechia|France|Hungary|Israel|Italy|Spain|Switzerland|Turkey|United Kingdom 1
United States|Austria|Brazil|Chile|France|Greece|Italy|Japan|Oman|Russian Federation|Spain|Switzerland|Turkey|United Kingdom 1
United States|Austria|Bulgaria|Czechia|Germany|Norway|Poland|Romania|Spain 1
United States|Austria|Canada|China|Czech Republic|Denmark|Finland|France|Germany|Greece|Hong Kong|India|Italy|Netherlands|New Zealand|Peru|Poland|Russian Federation|Slovakia|Spain|Taiwan|Tunisia|Ukraine|United Kingdom|Vietnam 1
United States|Austria|France|Germany|Italy|Japan|Poland|Spain|Switzerland|United Kingdom 1
United States|Austria|Germany|Japan|Poland|Switzerland|United Kingdom 1
United States|Belgium|France|Germany|Hungary|Italy|Netherlands|Poland|Spain 1
United States|Belgium|Germany|India|Israel|Poland|Romania|Russian Federation|Serbia|Spain|Ukraine|United Kingdom 1
United States|Canada|France|Netherlands|Spain|United Kingdom 1
United States|Canada|India|Puerto Rico 1
United States|Canada|Japan 1
United States|Czech Republic|France|Germany|Hong Kong|Hungary|India|Italy|Korea, Republic of|Pakistan|Russian Federation 1
United States|France|Germany|Spain|United Kingdom 1
United States|Germany|United Kingdom 1

Sites per Study

Site_count Study_Count
1 71
2 2
3 5
4 3
5 2
6 2
7 3
8 1
9 1
10 2
11 4
12 2
13 2
15 3
17 3
18 1
20 1
22 2
25 1
27 1
28 1
30 2
31 1
33 2
34 1
35 1
42 1
45 2
47 1
48 1
51 2
52 1
55 1
59 1
101 1
110 1
115 1
345 1

Phase

Phase Study_Count
Phase 3 45
Phase 2 37
Phase 1 15
Phase 4 12
N/A 10
Phase 1/Phase 2 7
Phase 2/Phase 3 6
Early Phase 1 2

Number of Arms

Number_of_Arms Count_of_Studies
1 53
2 46
3 10
4 7
5 2
10 2
25 1
NA 13

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 3.00 5.00 12.00 16.00000 8 17.00 9.0000 20.00
1st Qu. 7.75 45.00 28.25 26.00000 23 18.25 34.7500 25.75
Median 12.50 90.00 36.00 36.00000 45 27.50 74.0000 43.50
Mean 12.50 121.40 37.50 37.14286 52 39.00 106.9545 78.50
3rd Qu. 17.25 142.25 41.50 43.00000 75 42.00 146.2500 98.00
Max. 22.00 450.00 84.00 70.00000 132 100.00 414.0000 261.00

Trial Group Type

group_type Group_Count
Experimental 189
Active Comparator 27
Placebo Comparator 27
NA 13
Other 8
No Intervention 7

Intervention Model

intervention_model Study_Count
Parallel Assignment 59
Single Group Assignment 59
Crossover Assignment 8
Sequential Assignment 5
NA 3

Primary Purpose

primary_purpose Study_Count
Treatment 122
Prevention 3
Basic Science 2
Diagnostic 2
Other 2
Supportive Care 2
NA 1

Observational Studies

Studies by Country

Country Study_Count
NA 9
France 6
United States 3
China 2
Japan 2
United Kingdom 2
Austria|Belgium|France|Germany|Greece|Netherlands|Spain|United Kingdom 1
Canada 1
Italy 1
Korea, Republic of 1
United States|Australia|Bulgaria|Canada|Czech Republic|France|Germany|Hong Kong|Hungary|India|Italy|Pakistan|Peru|Poland|Puerto Rico|Russian Federation|Spain|Sweden|Tunisia|Ukraine|United Kingdom 1
United States|Austria|Czechia|Germany|Japan|Norway|Switzerland 1
United States|Canada 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 22
2 1
4 1
7 1
8 1
20 1
22 1
26 1
29 1
36 1
72 1

Enrollment Metrics

Measure Observational
Min 10.0000
1st Qu 41.0000
Median 153.0000
Mean 898.9677
3rd Qu 425.0000
Max 20000.0000

Observation Model

observational_model Study_Count
Cohort 14
Case-Only 8
NA 4
Case-Control 2
Case Control 2
Other 2

Time Perspective

time_perspective Study_Count
Prospective 19
NA 5
Cross-Sectional 3
Other 3
Retrospective 2

Registries

Studies by Country

Country Study_Count
United States 5
China 1
France 1
Germany 1
NA 1

Sites per Study

Site_count Study_Count
1 8
3 1

Enrollment Metrics

Measure Registries
Min 1.0000
1st Qu 150.0000
Median 386.0000
Mean 338.8889
3rd Qu 467.0000
Max 707.0000

Registry Model

observational_model Study_Count
Cohort 7
Case-Only 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 6
Cross-Sectional 3

Follow-up

target_duration Study_Count
1 Year 3
12 Months 2
1 Day 1
2 Months 1
3 Months 1
6 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT02134171 Early Predictive Factors of Cardiac and Cerebral Involvement in TMA https://ClinicalTrials.gov/show/NCT02134171 Completed Assistance Publique - Hôpitaux de Paris 2017-07-04
NCT03393975 A Study of Prophylactic and On-demand Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) With BAX 930 (rADAMTS13) https://ClinicalTrials.gov/show/NCT03393975 Recruiting Shire 2023-02-01
NCT02553317 Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT02553317 Completed Ablynx 2017-08-31
NCT01988506 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases https://ClinicalTrials.gov/show/NCT01988506 Recruiting Assistance Publique - Hôpitaux de Paris 2020-08-13
NCT03275454 A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT03275454 Recruiting Sanofi 2022-05-31
NCT03258866 The Study of Different Dose Rituximab in the Treatment of ITP https://ClinicalTrials.gov/show/NCT03258866 Completed Shandong University 2015-12-31
NCT03222843 Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient https://ClinicalTrials.gov/show/NCT03222843 Recruiting Jiangsu HengRui Medicine Co., Ltd. 2020-06-30
NCT03177629 H. Pylori Eradication for Moderate ITP https://ClinicalTrials.gov/show/NCT03177629 Recruiting Seoul National University Hospital 2020-06-30
NCT03172676 Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT03172676 Recruiting Assiut University 2020-06-01
NCT01808521 A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura https://ClinicalTrials.gov/show/NCT01808521 Completed Bloodworks 2017-07-31
NCT03010202 The PROLONG Trial - Rituximab Maintenance Therapy in ITP https://ClinicalTrials.gov/show/NCT03010202 Recruiting Ostfold Hospital Trust 2023-12-31
NCT02914054 Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone https://ClinicalTrials.gov/show/NCT02914054 Completed Isfahan University of Medical Sciences 2017-09-15
NCT04014413 Safety and Efficacy of Fecal Microbiota Transplantation https://ClinicalTrials.gov/show/NCT04014413 Recruiting Chinese University of Hong Kong 2023-10-31
NCT02878603 Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES) https://ClinicalTrials.gov/show/NCT02878603 Active, not recruiting Ablynx 2020-10-31
NCT01963260 Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) https://ClinicalTrials.gov/show/NCT01963260 Completed Merck Sharp & Dohme Corp. 2015-04-26
NCT02939573 A Randomized Multicenter Study for Isolated Skin Vasculitis https://ClinicalTrials.gov/show/NCT02939573 Recruiting University of Pennsylvania 2023-04-30
NCT03395210 A Study of PRN1008 in Adult Patients With Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT03395210 Recruiting Principia Biopharma Inc. 2021-06-30
NCT02540720 The Research of Standard Diagnosis and Treatment for Severe HSP in Children https://ClinicalTrials.gov/show/NCT02540720 Recruiting Nanjing Children’s Hospital 2020-07-31
NCT02532790 The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children https://ClinicalTrials.gov/show/NCT02532790 Recruiting Nanjing Children’s Hospital 2020-07-31
NCT02532777 The Research of Standard Diagnosis and Treatment for HSPN in Children https://ClinicalTrials.gov/show/NCT02532777 Recruiting Nanjing Children’s Hospital 2020-07-31
NCT02281370 Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects https://ClinicalTrials.gov/show/NCT02281370 Completed GlaxoSmithKline 2014-12-24
NCT02273960 Study to Evaluate Safety and Efficacy in Adult Subjects With ITP https://ClinicalTrials.gov/show/NCT02273960 Completed Bristol-Myers Squibb 2018-01-22
NCT02216084 Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP) https://ClinicalTrials.gov/show/NCT02216084 Completed Shire 2016-02-29
NCT02201290 A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT02201290 Completed Novartis 2017-07-04
NCT02076399 A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT02076399 Completed Rigel Pharmaceuticals 2016-04-21
NCT01289509 A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects https://ClinicalTrials.gov/show/NCT01289509 Completed Eisai Inc. 2011-03-31
NCT03922308 Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) https://ClinicalTrials.gov/show/NCT03922308 Recruiting Shire 2021-07-01
NCT01910831 Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands https://ClinicalTrials.gov/show/NCT01910831 Completed The Center for Clinical and Cosmetic Research 2014-01-31
NCT02334813 Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT02334813 Completed University Hospital, Essen 2015-01-31
NCT01762761 Eltrombopag Phase III Study In Chinese Chronic ITP Patients https://ClinicalTrials.gov/show/NCT01762761 Completed Novartis 2014-06-05
NCT01734044 rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP https://ClinicalTrials.gov/show/NCT01734044 Completed Shandong University 2014-07-31
NCT01730352 Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients https://ClinicalTrials.gov/show/NCT01730352 Completed Federal University of São Paulo 2011-05-31
NCT01719692 Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT01719692 Completed Institute of Hematology & Blood Diseases Hospital 2015-10-31
NCT01713855 Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT01713855 Completed Neufeld, Ellis J, MD, PhD NA
NCT01713738 Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT01713738 Completed Neufeld, Ellis J, MD, PhD 2005-12-31
NCT01652599 Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT https://ClinicalTrials.gov/show/NCT01652599 Completed Hospital Universitario Dr. Jose E. Gonzalez 2013-06-30
NCT02077192 Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT02077192 Active, not recruiting Rigel Pharmaceuticals 2020-03-31
NCT01610180 Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) https://ClinicalTrials.gov/show/NCT01610180 Completed Fondazione Progetto Ematologia 2018-06-30
NCT01554514 Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT01554514 Completed Washington University School of Medicine 2020-02-14
NCT01549054 A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501 https://ClinicalTrials.gov/show/NCT01549054 Completed Eisai Inc. 2012-06-30
NCT01525836 rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP https://ClinicalTrials.gov/show/NCT01525836 Completed Shandong University 2013-12-31
NCT01520909 Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body. https://ClinicalTrials.gov/show/NCT01520909 Completed GlaxoSmithKline 2014-01-31
NCT01444417 Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients https://ClinicalTrials.gov/show/NCT01444417 Completed Amgen 2015-02-28
NCT01437384 Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine. https://ClinicalTrials.gov/show/NCT01437384 Completed Eisai Inc. 2012-03-31
NCT01390649 A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT01390649 Completed CSL Behring 2014-09-30
NCT01356511 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT01356511 Completed Shandong University 2014-05-31
NCT01327872 Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects https://ClinicalTrials.gov/show/NCT01327872 Completed Eisai Inc. 2011-04-30
NCT00351468 EXTEND (Eltrombopag Extended Dosing Study) https://ClinicalTrials.gov/show/NCT00351468 Completed Novartis 2015-07-31
NCT04132050 A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 https://ClinicalTrials.gov/show/NCT04132050 Recruiting Kissei Pharmaceutical Co., Ltd. 2021-12-31
NCT04074187 A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) https://ClinicalTrials.gov/show/NCT04074187 Recruiting Sanofi 2021-01-31
NCT03866577 Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients https://ClinicalTrials.gov/show/NCT03866577 Recruiting Momenta Pharmaceuticals, Inc. 2022-04-30
NCT03830749 Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT03830749 Recruiting Humanity & Health Medical Group Limited 2020-12-31
NCT03692754 Atorvastatin in Management of Newly Diagnosed ITP https://ClinicalTrials.gov/show/NCT03692754 Recruiting Shandong University 2021-12-01
NCT03664518 to Evaluate the Efficacy and Safety of Eltrombopag for Thrombocytopenia With Chronic HBV Infection https://ClinicalTrials.gov/show/NCT03664518 Recruiting Institute of Hematology & Blood Diseases Hospital 2019-10-31
NCT03647852 Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura https://ClinicalTrials.gov/show/NCT03647852 Recruiting Children’s Hospital of Fudan University 2021-10-30
NCT01506414 Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) https://ClinicalTrials.gov/show/NCT01506414 Completed Shandong University 2013-08-31
NCT03524612 A Study to Assess the Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP https://ClinicalTrials.gov/show/NCT03524612 Recruiting Novartis 2022-06-30
NCT03499808 S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis https://ClinicalTrials.gov/show/NCT03499808 Active, not recruiting Southwest Oncology Group 2021-10-30
NCT03412188 The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP. https://ClinicalTrials.gov/show/NCT03412188 Recruiting Ain Shams University 2019-11-30
NCT00305435 Safety Study of AMG 531 in Japanese Subjects With ITP https://ClinicalTrials.gov/show/NCT00305435 Completed Kyowa Kirin Co., Ltd. 2006-11-30
NCT01172015 NATURAL KILLER CELLS IN IMMUNOLOGIC THROMBOCYTOPENIC PURpura of Adults https://ClinicalTrials.gov/show/NCT01172015 Completed Assistance Publique Hopitaux De Marseille 2012-06-30
NCT01151423 Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) https://ClinicalTrials.gov/show/NCT01151423 Completed Ablynx 2014-03-31
NCT01143038 Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim https://ClinicalTrials.gov/show/NCT01143038 Completed Amgen 2013-09-20
NCT00370331 RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag https://ClinicalTrials.gov/show/NCT00370331 Completed GlaxoSmithKline 2008-07-31
NCT01107951 Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP https://ClinicalTrials.gov/show/NCT01107951 Completed Hospital Universitario Dr. Jose E. Gonzalez 2010-04-30
NCT01098487 A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT01098487 Completed GlaxoSmithKline 2014-05-31
NCT00301613 Mycophenolate Mofetil (MMF) Versus Intravenous CTX Pulses in the Treatment of Adult Severe HSPN https://ClinicalTrials.gov/show/NCT00301613 Completed Nanjing University School of Medicine 2005-05-31
NCT01072162 Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect https://ClinicalTrials.gov/show/NCT01072162 Completed GlaxoSmithKline 2010-04-07
NCT01071954 A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura https://ClinicalTrials.gov/show/NCT01071954 Completed Amgen 2017-01-12
NCT00909077 The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00909077 Completed Copenhagen University Hospital at Herlev 2012-06-01
NCT00908037 Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00908037 Completed GlaxoSmithKline 2014-02-01
NCT00907751 Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00907751 Completed Assistance Publique - Hôpitaux de Paris 2013-08-31
NCT00907478 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) https://ClinicalTrials.gov/show/NCT00907478 Completed Amgen 2014-01-09
NCT00888901 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag https://ClinicalTrials.gov/show/NCT00888901 Completed Medical University of Vienna 2011-03-31
NCT00860600 Safety and Efficacy Study of PG2 to Treat Idiopathic Thrombocytopenic Purpura (ITP) Patients https://ClinicalTrials.gov/show/NCT00860600 Completed PhytoHealth Corporation 2011-08-31
NCT02076412 A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT02076412 Completed Rigel Pharmaceuticals 2016-08-31
NCT01621204 A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients https://ClinicalTrials.gov/show/NCT01621204 Completed McMaster University 2019-06-30
NCT00828750 Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00828750 Completed GlaxoSmithKline 2011-02-28
NCT04070599 Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura. https://ClinicalTrials.gov/show/NCT04070599 Completed University Hospital, Bordeaux 2014-03-05
NCT03690375 Broad Band Light With and Without Radiofrequency Microneedling for Treating Senile Purpura https://ClinicalTrials.gov/show/NCT03690375 Completed Siperstein Dermatology 2019-10-15
NCT03275740 A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 https://ClinicalTrials.gov/show/NCT03275740 Recruiting Pfizer 2020-10-21
NCT03222687 Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis https://ClinicalTrials.gov/show/NCT03222687 Completed Shandong University 2017-05-31
NCT00774202 Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP https://ClinicalTrials.gov/show/NCT00774202 Completed Weill Medical College of Cornell University 2008-02-29
NCT00770562 A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00770562 Completed Hoffmann-La Roche 2008-07-31
NCT00749112 Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias https://ClinicalTrials.gov/show/NCT00749112 Completed Hospital Universitario Dr. Jose E. Gonzalez 2010-08-31
NCT00718692 Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00718692 Completed Symphogen A/S 2011-08-31
NCT00713193 Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) https://ClinicalTrials.gov/show/NCT00713193 Completed Ohio State University 2017-09-20
NCT00706342 Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00706342 Completed Rigel Pharmaceuticals 2010-04-30
NCT00699140 Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00699140 Completed Grifols Biologicals, LLC 2013-12-31
NCT00688272 Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag https://ClinicalTrials.gov/show/NCT00688272 Completed GlaxoSmithKline 2008-09-25
NCT00657410 Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00657410 Completed Gruppo Italiano Malattie EMatologiche dell’Adulto 2016-02-29
NCT00632242 ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders https://ClinicalTrials.gov/show/NCT00632242 Completed Archemix Corp. 2008-12-31
NCT00625443 Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 https://ClinicalTrials.gov/show/NCT00625443 Completed Eisai Inc. 2009-06-30
NCT00621894 Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation https://ClinicalTrials.gov/show/NCT00621894 Completed GlaxoSmithKline 2009-05-01
NCT00603642 P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00603642 Completed Amgen 2009-04-13
NCT00540423 Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00540423 Completed GlaxoSmithKline 2008-12-31
NCT00515203 Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects https://ClinicalTrials.gov/show/NCT00515203 Completed Amgen 2009-03-31
NCT00511147 IGIV Study for Chronic ITP Patients Ages 3-70 https://ClinicalTrials.gov/show/NCT00511147 Completed Grifols Biologicals, LLC 2014-04-30
NCT00508820 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP https://ClinicalTrials.gov/show/NCT00508820 Completed Amgen 2011-01-01
NCT00504075 A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00504075 Completed Bio Products Laboratory 2011-08-31
NCT00487968 Eltrombopag Taste Testing in Healthy Adult Volunteers https://ClinicalTrials.gov/show/NCT00487968 Completed GlaxoSmithKline NA
NCT00486421 Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00486421 Completed Mayo Clinic 2008-05-31
NCT00475423 A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura. https://ClinicalTrials.gov/show/NCT00475423 Completed Hoffmann-La Roche 2011-08-31
NCT00467571 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00467571 Completed Mahidol University 2008-09-30
NCT00451594 High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITP https://ClinicalTrials.gov/show/NCT00451594 Completed Cooperative Study Group A for Hematology 2010-12-31
NCT00442871 Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment https://ClinicalTrials.gov/show/NCT00442871 Completed GlaxoSmithKline 2008-01-03
NCT00441090 Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00441090 Completed Eisai Inc. 2009-01-31
NCT00440037 Open Label Extension Study of AMG 531 in Japanese Subjects With ITP https://ClinicalTrials.gov/show/NCT00440037 Completed Kyowa Kirin Co., Ltd. 2011-07-31
NCT00426270 Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults https://ClinicalTrials.gov/show/NCT00426270 Completed Octapharma 2008-09-30
NCT00425724 HSP-glomerulonephritis Trial: MP vs CyA https://ClinicalTrials.gov/show/NCT00425724 Completed Oulu University Hospital 2007-02-28
NCT00424177 Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT) https://ClinicalTrials.gov/show/NCT00424177 Completed GlaxoSmithKline 2008-08-31
NCT00415532 Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00415532 Completed Amgen 2008-11-07
NCT00376077 A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. https://ClinicalTrials.gov/show/NCT00376077 Completed The Hospital for Sick Children 2016-03-31
NCT00392951 Sirolimus for Autoimmune Disease of Blood Cells https://ClinicalTrials.gov/show/NCT00392951 Completed Children’s Hospital of Philadelphia 2016-02-29
NCT00372892 Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00372892 Completed McMaster University 2010-12-31
NCT00362349 Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients https://ClinicalTrials.gov/show/NCT00362349 Completed CSL Limited 2008-10-31
NCT00359463 Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment https://ClinicalTrials.gov/show/NCT00359463 Completed GlaxoSmithKline 2007-03-07
NCT00272610 Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin https://ClinicalTrials.gov/show/NCT00272610 Completed University of Michigan NA
NCT00220727 Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP https://ClinicalTrials.gov/show/NCT00220727 Completed Grifols Therapeutics LLC 2003-10-31
NCT00190229 Efficacy of Steroid Versus Steroid Plus Cyclophosphamide for Severe Henoch-Schoenlein Purpura https://ClinicalTrials.gov/show/NCT00190229 Completed Assistance Publique - Hôpitaux de Paris 2008-01-31
NCT00168038 Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10 https://ClinicalTrials.gov/show/NCT00168038 Completed CSL Behring NA
NCT00162006 Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00162006 Completed Shire 2003-12-01
NCT00157079 Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders https://ClinicalTrials.gov/show/NCT00157079 Completed Shire 2003-12-16
NCT00151840 Efficacy and Safety of IVIG-L in ITP Patients https://ClinicalTrials.gov/show/NCT00151840 Completed Sanquin Plasma Products BV NA
NCT00128882 Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D https://ClinicalTrials.gov/show/NCT00128882 Completed University of Aarhus 2008-01-31
NCT00117143 Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00117143 Completed Amgen 2004-07-19
NCT00116688 Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00116688 Completed Amgen 2010-01-31
NCT00111475 Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00111475 Completed Amgen 2004-06-17
NCT00102336 AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy https://ClinicalTrials.gov/show/NCT00102336 Completed Amgen 2006-12-01
NCT00102323 AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy https://ClinicalTrials.gov/show/NCT00102323 Completed Amgen 2006-09-01
NCT00002250 A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00002250 Completed NIH AIDS Clinical Trials Information Service NA
NCT00102739 SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00102739 Completed GlaxoSmithKline 2007-01-31
NCT00010387 Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease https://ClinicalTrials.gov/show/NCT00010387 Completed Office of Rare Diseases (ORD) 2007-08-31
NCT00005652 Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00005652 Completed Office of Rare Diseases (ORD) 2007-08-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03369314 Observational Study of the Use of octaplasLG®. https://ClinicalTrials.gov/show/NCT03369314 Recruiting Octapharma 2020-12-31
NCT02317133 Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura https://ClinicalTrials.gov/show/NCT02317133 Completed Centre Hospitalier Universitaire de Nīmes 2017-07-11
NCT03219723 Drug Use Surveillance of Takecab for “Supplement to Helicobacter Pylori Eradication” https://ClinicalTrials.gov/show/NCT03219723 Completed Takeda 2017-04-30
NCT03187652 A Prospective Study on the Long-Term Vascular Burden in TTP Patients https://ClinicalTrials.gov/show/NCT03187652 Recruiting Lawson Health Research Institute 2021-01-01
NCT02891109 Regulatory B Cells and Chronic Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT02891109 Completed University Hospital, Brest 2015-09-30
NCT02476292 Impact of Vasculitis on Employment and Income https://ClinicalTrials.gov/show/NCT02476292 Completed University of South Florida 2016-01-31
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions https://ClinicalTrials.gov/show/NCT01931644 Recruiting Sanguine Biosciences 2025-08-31
NCT01672151 Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT01672151 Completed First Affiliated Hospital of Suzhou Medical College 2012-08-31
NCT01668615 Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytopenia https://ClinicalTrials.gov/show/NCT01668615 Completed First Affiliated Hospital of Suzhou Medical College 2012-08-31
NCT01571349 Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT01571349 Completed Samsung Medical Center 2012-12-31
NCT01510873 Health-related Quality of Life and Fatigue in Adult Patients With Primary Immune Thrombocytopenic Purpura (pITP) https://ClinicalTrials.gov/show/NCT01510873 Completed Gruppo Italiano Malattie EMatologiche dell’Adulto 2014-01-31
NCT01439321 Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim https://ClinicalTrials.gov/show/NCT01439321 Completed GlaxoSmithKline 2011-06-30
NCT01435525 Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation https://ClinicalTrials.gov/show/NCT01435525 Completed AstraZeneca 2014-03-31
NCT01416311 Drug Use Investigation for REVOLADE (ITP) https://ClinicalTrials.gov/show/NCT01416311 Active, not recruiting Novartis 2020-10-20
NCT03605511 TTP and aHUS in Complicated Pregnancies https://ClinicalTrials.gov/show/NCT03605511 Recruiting University College, London 2020-03-14
NCT04071496 Diagnostic of Chronic Thrombocytopenia https://ClinicalTrials.gov/show/NCT04071496 Completed University Hospital, Bordeaux 2012-03-12
NCT04070612 National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia. https://ClinicalTrials.gov/show/NCT04070612 Completed University Hospital, Bordeaux 2012-06-08
NCT04057703 Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia. https://ClinicalTrials.gov/show/NCT04057703 Completed University Hospital, Bordeaux 2016-12-04
NCT03832881 The United Kingdom Thrombotic Thrombocytopenic Purpura Registry (UK TTP Registry) https://ClinicalTrials.gov/show/NCT03832881 Recruiting University College, London 2023-11-30
NCT03519672 Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP] https://ClinicalTrials.gov/show/NCT03519672 Completed Shire 2019-04-08
NCT01257269 Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome) https://ClinicalTrials.gov/show/NCT01257269 Recruiting University Hospital Inselspital, Berne 2030-10-31
NCT02085993 Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training https://ClinicalTrials.gov/show/NCT02085993 Completed Amgen 2015-11-30
NCT00960713 The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders https://ClinicalTrials.gov/show/NCT00960713 Completed University Hospital, Toulouse 2012-01-31
NCT00861224 Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology https://ClinicalTrials.gov/show/NCT00861224 Completed Amgen 2006-10-31
NCT03216577 Outcomes of Purpura FULminans in Adults - The hOPeFUL Study https://ClinicalTrials.gov/show/NCT03216577 Completed Henri Mondor University Hospital 2018-03-08
NCT02967068 VCRC Tissue Repository https://ClinicalTrials.gov/show/NCT02967068 Recruiting University of Pennsylvania 2022-09-30
NCT04056507 Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT04056507 Completed University Hospital, Bordeaux 2015-09-30
NCT00454857 Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) https://ClinicalTrials.gov/show/NCT00454857 Completed Amgen 2008-06-30
NCT00426686 ADAMTS13 in Thrombotic Thrombocytopenic Purpura https://ClinicalTrials.gov/show/NCT00426686 Completed Assistance Publique - Hôpitaux de Paris 2009-03-31
NCT00005570 An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers https://ClinicalTrials.gov/show/NCT00005570 Completed National Institutes of Health Clinical Center (CC) NA
NCT00643929 LENS - Long-term Eltrombopag Observational Study https://ClinicalTrials.gov/show/NCT00643929 Completed GlaxoSmithKline 2013-03-31
NCT00005302 Drug Etiology of Aplastic Anemia and Related Dyscrasias https://ClinicalTrials.gov/show/NCT00005302 Completed National Heart, Lung, and Blood Institute (NHLBI) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03410290 Journey of Patients With Vasculitis From First Symptom to Diagnosis https://ClinicalTrials.gov/show/NCT03410290 Completed University of Pennsylvania 2018-05-21
NCT03123497 Assessment of Quality of Life of Children With Chronic Idiopathic Thrombocytopenic Purpura (Kid’s ITP Tools) https://ClinicalTrials.gov/show/NCT03123497 Recruiting University Hospital, Angers 2020-10-31
NCT02878018 Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis https://ClinicalTrials.gov/show/NCT02878018 Active, not recruiting Liaoning University of Traditional Chinese Medicine 2019-03-31
NCT02593565 Vasculitis Pregnancy Registry https://ClinicalTrials.gov/show/NCT02593565 Recruiting University of Pennsylvania 2021-12-31
NCT02238795 Sepsis-Associated Purpura Fulminans International Registry - Europe https://ClinicalTrials.gov/show/NCT02238795 Recruiting Jena University Hospital 2019-12-31
NCT02190916 Vasculitis Illness Perception (VIP) Study https://ClinicalTrials.gov/show/NCT02190916 Completed University of South Florida 2013-10-31
NCT02176070 Reproductive Health in Men and Women With Vasculitis https://ClinicalTrials.gov/show/NCT02176070 Completed University of South Florida 2012-03-31
NCT01064336 Promacta Pregnancy Registry https://ClinicalTrials.gov/show/NCT01064336 Completed GlaxoSmithKline 2014-07-31
NCT02190929 Educational Needs of Patients With Systemic Vasculitis https://ClinicalTrials.gov/show/NCT02190929 Completed University of South Florida 2014-02-28